Deep 6 AI vs Mendel
Two platforms that read unstructured clinical text to answer research questions, separated by what they are ultimately for. Deep 6 is a trial platform, covering feasibility and cohort building at design through to matching patients and sites in real time across therapeutic areas. Mendel is an abstraction platform of which trial prescreening is one application, with a hybrid architecture pairing language models and symbolic reasoning specifically because generation alone produces confident errors, and it can run inside the customer's own environment. If the mandate is enrol more patients, Deep 6 is built end to end for that. If it is stop paying clinicians to read charts, across trials and observational research alike, Mendel is the broader capability and the safer residency answer. Neither publishes how often an eligible patient never surfaces at all.
- It reads unstructured clinical data across notes, pathology, genomics and laboratory reports to match patients and sites in real time, across therapeutic areas rather than one specialty.
- Functional coverage spans feasibility and cohort building at study design through to enrolment, so sponsors and sites use the same platform.
- It quantifies how much decisive eligibility information sits in unstructured data, which is the argument for reading notes rather than filtering codes.
- The architecture is deliberately hybrid, pairing language models with symbolic reasoning over a clinical hypergraph because generation alone produces confident abstraction errors.
- It can be hosted inside the customer's own environment, which is the strongest residency position among the trial and abstraction vendors here.
- The capability serves cohort building and observational research as well as prescreening, so one platform covers several research functions.
Side by Side
| Axis | D Deep 6 AI |
M Mendel |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both should be asked for the false negative rate on eligibility screening, which neither publishes and which is the only real measure of a matching system, since a patient who was eligible and never surfaced is invisible in every metric either reports. Deep 6 publishes no attestation scoped to the platform, no business associate terms and no governance framework; Mendel publishes no security attestation or trust centre. Both inherit documentation bias, so patients with sparse or fragmented records are systematically less likely to be found regardless of eligibility.